Coya Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Coya Therapeutics (COYA).

Price Target Range — 11 Quarters

Analyst Consensus — 7 Analysts

7Buy

Consensus RatingBuy# Analysts7Avg. Consensus PT$16Upside to Avg. PT+274.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 15, 2026	BTIG	Thomas Shrader	Maintained	Buy	$16
Aug 24, 2026	Roth Capital	Boobalan Pachaiyappan	Maintained	Buy	$12
Aug 12, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$14
Jun 12, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$14
Jun 5, 2026	Roth Capital	Boobalan Pachaiyappan	Initiate	Buy	$12
Apr 10, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$15
Mar 23, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$18
Mar 19, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$15
Mar 16, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$14
Mar 16, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$15
Feb 18, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$15
Feb 2, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$18
Jan 21, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$15
Jan 8, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$14
Jan 8, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$15
Jan 5, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$15
Dec 23, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$15
Dec 9, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$15
Nov 14, 2025	Chardan Capital	Keay Nakae	Maintained	Buy	$14
Nov 13, 2025	BTIG	Thomas Shrader	PT Raise	Buy	$15→$16

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
BTIG Reiterates Buy on Coya Therapeutics, Maintains $16 Price Target

BTIG analyst Thomas Shrader reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $16 price target.

Benzinga Newsdesk

PRO
Roth Capital Reiterates Buy on Coya Therapeutics, Maintains $12 Price Target

Roth Capital analyst Boobalan Pachaiyappan reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $12 price target.

Benzinga Newsdesk

This Onto Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Top Wall Street analysts changed outlook for top names. See all changes on analyst ratings page. ONTO rated Buy with $350 PT by Deutsche Bank.

Avi Kapoor

PRO
Roth Capital Initiates Coverage On Coya Therapeutics with Buy Rating, Announces Price Target of $12

Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Coya Therapeutics (NASDAQ:COYA) with a Buy rating and announces Price Target of $12.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Coya Therapeutics, Maintains $18 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $18 price target.

Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on Coya Therapeutics, Maintains $15 Price Target

D. Boral Capital analyst Jason Kolbert maintains Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $15 price target.

Benzinga Newsdesk

Coya Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Coya Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
BTIG Reiterates Buy on Coya Therapeutics, Maintains $16 Price Target

PRO
Roth Capital Reiterates Buy on Coya Therapeutics, Maintains $12 Price Target

This Onto Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

PRO
Roth Capital Initiates Coverage On Coya Therapeutics with Buy Rating, Announces Price Target of $12

PRO
HC Wainwright & Co. Reiterates Buy on Coya Therapeutics, Maintains $18 Price Target

PRO
D. Boral Capital Maintains Buy on Coya Therapeutics, Maintains $15 Price Target

People Also Watch

People Also Watch

Coya Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Coya Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBTIG Reiterates Buy on Coya Therapeutics, Maintains $16 Price Target

PRORoth Capital Reiterates Buy on Coya Therapeutics, Maintains $12 Price Target

This Onto Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

PRORoth Capital Initiates Coverage On Coya Therapeutics with Buy Rating, Announces Price Target of $12

PROHC Wainwright & Co. Reiterates Buy on Coya Therapeutics, Maintains $18 Price Target

PROD. Boral Capital Maintains Buy on Coya Therapeutics, Maintains $15 Price Target

People Also Watch

People Also Watch

PRO
BTIG Reiterates Buy on Coya Therapeutics, Maintains $16 Price Target

PRO
Roth Capital Reiterates Buy on Coya Therapeutics, Maintains $12 Price Target

PRO
Roth Capital Initiates Coverage On Coya Therapeutics with Buy Rating, Announces Price Target of $12

PRO
HC Wainwright & Co. Reiterates Buy on Coya Therapeutics, Maintains $18 Price Target

PRO
D. Boral Capital Maintains Buy on Coya Therapeutics, Maintains $15 Price Target